Shares of Magnolia Oil & Gas Corporation (MGY Quick QuoteMGY ) stock has shown no substantial movement since second-quarter 2021 earnings announcement on Aug 2. In fact, the firm’s shares failed to display an uptrend despite impressive bottom-line and top-line performances as well as an upbeat third-quarter production guidance, which indicates growth from the sequential quarter’s reported figure.
The company reported second-quarter adjusted net income per share of 56 cents, beating the Zacks Consensus Estimate of 37 cents. The bottom line reversed the year-ago quarter’s loss of 8 cents per share.
This outperformance can be primarily attributed to better-than-anticipated production volumes. The South Texas-focused company’s average daily oil output of 31,897 barrels per day surpassed the Zacks Consensus Estimate of 30,734 barrels.
Total revenues came in at $250.73 million, ahead of the Zacks Consensus Estimate of $229 million. Moreover, the top line rose 202.7% from the year-ago level of $82.84 million.
Best Oil Stocks To Buy Right Now: Cheniere Energy, Inc.(LNG)
Cheniere Energy, Inc., incorporated on March 25, 1983, is an energy company primarily engaged in liquefied natural gas (LNG) related businesses. The Company operates through two segments: LNG terminal business and LNG and natural gas marketing business The Company owns and operates the Sabine Pass LNG terminal in Louisiana through its ownership interest in and management agreements with Cheniere Energy Partners, L.P. (Cheniere Partners), which is a publicly traded limited partnership. The Company owns approximately 100% of the general partner interest in Cheniere Partners and over 80% of Cheniere Energy Partners LP Holdings, LLC (Cheniere Holdings), which is a publicly traded limited liability company that owns approximately 56% limited partner interest in Cheniere Partners.
The Sabine Pass LNG terminal has operational regasification facilities owned by Cheniere Partners subsidiary, Sabine Pass LNG, L.P. (SPLNG) that includes existing infrastructure of over five LNG storage tanks with capacity of approximately 16.9 billion cubic feet equivalent (Bcfe), over two docks that can accommodate vessels with nominal capacity of approximately 266,000 cubic meters and vaporizers with regasification capacity of approximately 4.0 billion cubic feet per day (Bcf/d). Cheniere Partners is developing and constructing natural gas liquefaction facilities (Sabine Pass Liquefaction Project) at the Sabine Pass LNG terminal adjacent to the existing regasification facilities through a subsidiary, Sabine Pass Liquefaction, LLC (Sabine Pass Liquefaction). Cheniere Partners also owns a 94-mile pipeline that interconnects the Sabine Pass LNG terminal with a number of interstate pipelines (the Creole Trail Pipeline) through a subsidiary, Cheniere Creole Trail Pipeline, L.P. (CTPL).
The Company is developing and constructing a second natural gas liquefaction and export facility at the Corpus Christi LNG terminal, which is on over 2,000 acres of land that it owns or controls near Corpus Christi, Texas,! and a pipeline facility (the CCL Project) through its subsidiaries Corpus Christi Liquefaction, LLC (CCL) and Cheniere Corpus Christi Pipeline, L.P. (CCP), respectively. The CCL Project also includes a 23-mile, 48-inch natural gas supply pipeline that will interconnect the Corpus Christi LNG terminal with several interstate and intrastate natural gas pipelines (the Corpus Christi Pipeline). The Companys subsidiary, Cheniere Marketing, LLC (Cheniere Marketing), is engaged in the LNG and natural gas marketing business, and is developing a portfolio of long-term, short-term and spot LNG sale and purchase agreements (SPAs).
LNG Terminal Business
The Company is focused on the development of over two LNG terminal projects: the Sabine Pass LNG terminal in western Cameron Parish, Louisiana, less than four miles from the Gulf Coast on the Sabine-Neches Waterway and the Corpus Christi LNG terminal near Corpus Christi, Texas. Through Cheniere Partners, the Company has constructed and is operating regasification facilities at the Sabine Pass LNG terminal and are developing and constructing the Sabine Pass Liquefaction Project. It owns approximately 100% of the general partner interest in Cheniere Partners and over 80.1% of Cheniere Holdings, which owns approximately 55.9% limited partner interest in Cheniere Partners. The Company owns approximately 100% interest in the CCL Project. Sabine Pass Liquefaction has third-party SPAs, including BG Gulf Coast LNG, LLC (BG), Gas Natural Aprovisionamientos SDG S.A. (Gas Natural Fenosa), Korea Gas Corporation (KOGAS), GAIL (India) Limited (GAIL) and Centrica plc (Centrica). Corpus Christi Liquefaction’s third-party SPAs include Endesa Generacion, S.A., Iberdrola S.A., Gas Natural Fenosa LNG SL, Woodside Energy Trading Singapore Pte Ltd, PT Pertamina (Persero), Electricite de France, S.A. and EDP Energias de Portugal S.A.
LNG and Natural Gas Marketing Business
The Companys subsidiary, Cheniere Marketing, is engaged in ! the LNG a! nd natural gas marketing business and is developing a portfolio of long-term, short-term and spot LNG purchase and spot LNG SPAs. Cheniere Marketing purchases, transports and unloads commercial LNG cargoes into the Sabine Pass LNG terminal and other LNG terminals around the world.
- [By Money Morning Staff Reports]
He earned more than $100 million in a famous board room battle with RJR Nabisco, and recently he’s led the charge in pressing Caesars Entertainment Corp. (NASDAQ: CZR) to sell its assets. Rumors are swirling that the gambling giant will soon merge with Eldorado Resorts Inc. (NASDAQ: ERI). He also has stakes in CVR Energy Inc. (NYSE: CVI), Herbalife Nutrition Ltd. (NYSE: HLF), Cheniere Energy Inc. (NYSE: LNG), Newell Brands Inc. (NASDAQ: NWL), and of course, his firm Icahn Enterprises LP (NASDAQ: IEP).
- [By Motley Fool Transcribers]
Cheniere Energy Inc (NYSEMKT:LNG)Q42018 Earnings Conference CallFeb. 26, 2019, 10:00 a.m. ET
Prepared Remarks Questions and Answers Call Participants
Best Oil Stocks To Buy Right Now: Orocobre Limited (OROCF)
Orocobre Limited operates primarily in Argentina in the mining industry. The Company engages in the production ramp up of its Olaroz Lithium Facility and the operation of Borax Argentina S.A. (Borax Argentina). Its segments include Corporate, the Olaroz project, South American Salars and Borax Argentina. Its primary focus is on exploration for and development of lithium, potash and salar mineral deposits. The Company’s assets also include boron mines and processing facilities of Borax Argentina and a portfolio of brine exploration projects. Its Olaroz Lithium Facility is located in the Puna region of Jujuy Province in northern Argentina, over 230 kilometers northwest of the capital city of Jujuy. Borax Argentina operates over three open pit mines in Tincalayu, Sijes and Porvenir. Borax Argentina produces products, including minerals, such as ulexite, colemanite and hydroboracite; refined products, such as borax decahydrate, borax pentahydrate and borax anhydrous, and boric acid. Advisors’ Opinion:
- [By ]
In April 2018, Nemaska (OTCQX:NMKEF) drew nearly $100 million in investment from Japan’s SoftBank (OTCPK:SFTBY) group in exchange for a 9.9% interest in the company and access to lithium hydroxide produced by the company. In March 2018, CATL the world’s soon-to-be largest lithium battery manufacturer purchased a controlling stake in the Quebec Lithium project in consideration for $66 million. In February 2018, Korean steel giant, POSCO (PKX) announced a supply agreement and investment into Australian lithium miner Pilbara Minerals (OTCPK:PILBF). In January 2018, Toyota Tsusho (OTCPK:TYHOF), the strategic trading arm of Toyota Motors, invested approximately A$300 million in Orocobre (OTCPK:OROCF) in consideration for 15% of the company. Now, in April 2018, Swedish battery start-up NorthVolt has announced that it has signed an agreement for the supply of up to 5,000 metric tons per year of lithium hydroxide produced at Nemaska Lithium’s commercial plant in Shawinigan, Quebec. In connection with the supply of lithium chemicals, NorthVolt has agreed to deliver to Nemaska a 10 million euro promissory note that can be converted into voting shares of NorthVolt.
- [By ]
Early-stage lithium producer Orocobre (OTCPK:OROCF) has been busy developing its Argentine flag-ship asset at Olaroz. The company has managed to scale up the asset to around 12,000 T / year LCE with a nameplate production capacity of 17,500 T / year. Although the company has not achieved full production capacity at its asset, it has moved ahead with joint venture partner Toyota Tsusho (OTCPK:TYHOF) to develop plans for Phase 2. In January 2018, Orocobre announced that Toyota Tsusho would invest nearly $300 million for a 15% stake in the company, along with plans to double production capacity at Olaroz to 42,000 T LCE / year. The joint venture is also building a lithium hydroxide facility in Japan which will supply the local battery supply chain.
Best Oil Stocks To Buy Right Now: Impax Laboratories, Inc.(IPXL)
Impax Laboratories, Inc., incorporated on March 23, 1995, is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. The Company’s segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of the Company’s generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
The Company is focused on developing, manufacturing, selling and distributing solid dose and alternative dosage form products covering a range of therapeutic areas and drug-delivery mechanisms or product development formulations. The Company also develops, manufactures, sells and distributes specialty generic pharmaceuticals. It sells and distributes generic pharmaceutical products through over four sales channels, such as the Impax Generics sales channel, which includes generic pharmaceutical prescription products it sells directly to wholesalers, retail drug chains and others; Rx Partner sales channel, which includes generic prescription products sold through unrelated third-party pharmaceutical entities pursuant to alliance and collaboration agreements; Private Label sales channel, which includes generic pharmaceutical over-the-counter (OTC) and prescription products it sells to unrelated third parties and in-turn sells the product under t! heir own label, and OTC Partner sales channel, which includes sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical companies pursuant to alliance, collaboration and supply agreements. The Company markets over 140 generic pharmaceutical products representing dosage variations of approximately 60 different pharmaceutical compounds through its Impax Generics, and over five other generic pharmaceutical products, representing dosage variations of approximately two different pharmaceutical compounds, through its alliance and collaboration agreement partners.
Impax Specialty Pharma
The Impax Specialty Pharma segment is focused on the development and promotion through its specialty sales force of branded pharmaceutical products for the treatment of central nervous system (CNS) disorders, which include migraine, multiple sclerosis, PD and postherpetic neuralgia. The Company’s branded pharmaceutical product portfolio consists of commercial CNS products and development stage projects. The Impax Specialty Pharma segment is also engaged in the sale and distribution of over four other branded products, including Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches, and Albenza, indicated for the treatment of tapeworm infections.
The Company competes with Teva Pharmaceutical Industries Ltd., Allergan Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lannett Company, Inc., Lupin Pharmaceuticals, Inc., Endo International plc and Sandoz.
- [By Max Byerly]
News articles about Impax Laboratories (NASDAQ:IPXL) have trended somewhat positive on Sunday, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Impax Laboratories earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 43.4189030940397 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.